ImmuMed
Blood & Organ Banks · Minnesota, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
13878 Flay Ave N, Hugo, Minnesota, 55038...Phone Number
(763) 682-4470Website
www.immumeds.comRevenue
<$5 MillionIndustry
About ImmuMed
Is ImmuMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ImmuMed
Click to see if ImmuMed had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
ImmuMed, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ImmuMed is spiking on competitors!
Funding: Get notified immidiatlly once ImmuMed has new funding data
Product Launch: Get notified when ImmuMed launches new products
Website visits: Recent activity has been detected on your website
Check if ImmuMed has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ImmuMed recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
ImmuMed is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ImmuMed is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ImmuMed.
ImmuMed Tech Stack
A closer look at the technologies used by ImmuMed
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ImmuMed
Immumeds Inc. is a pioneering private therapeutic antibody company focused on revolutionizing organ transplantation through its proprietary antibody platform. Their lead product, Anti-Lymphocyte Globulin (ALG), has shown significant clinical success and is set for Phase III trials after being administered to over 52,000 organ transplant recipients.... Read More